@article{ART002814050},
author={Kouser fathima Firdose and Wajeeha Begum},
title={Effect of Majoon Idraare Haiz in Polycystic Ovarian Syndrome - A pilot study},
journal={CELLMED},
issn={3022-6805},
year={2022},
volume={12},
number={1},
pages={3-3},
doi={10.5667/CellMed.2022.003}
TY - JOUR
AU - Kouser fathima Firdose
AU - Wajeeha Begum
TI - Effect of Majoon Idraare Haiz in Polycystic Ovarian Syndrome - A pilot study
JO - CELLMED
PY - 2022
VL - 12
IS - 1
PB - Cellmed Orthocellular Medicine and Pharmaceutical Association
SP - 3
EP - 3
SN - 3022-6805
AB - Background & Objectives: Polycystic ovarian syndrome (PCOS) is one of the commonest endocrine abnormality in women of reproductive age affecting from 4% - 21% of the reproductive women and is characterized by chronic anovulation and hyperandrogenism. The aim of the study was to evaluate the effect of majoon idraare haiz in menstrual regulation and morphological changes in ovaries in poly cystic ovarian syndrome.
Methods: A Pilot study was carried out in the department of Ilmul qabalat wa amraze niswan, National institute of unani medicine, hospital, Bengaluru. Fifteen Patients of PCOS aged 18-35 diagnosed using Rotterdam criteria were included in the study. Patients with insulin sensitizing treatment within 3 months, hormonal treatment and those with h/o diabetes mellitus, hypertension, pregnant and lactating women were excluded. Majoon idraare haiz was administered orally at a dose of 10 g with 20 ml arq bed mushk once daily from fifth day of cycle for 21 days for three consecutive cycles. Primary outcome measure was menstrual regularity while changes in USG pelvis (normal ovarian morphology) was considered as secondary outcome measure. In addition, duration of flow and changes in basal metabolic index (BMI), modified Ferriman Gallwey (mFG) score, acanthosis nigricans were observed. Data were analyzed using, ANOVA, paired student ‘t’ test, fisher exact test.
Results: Changes in duration of cycle, duration and amount of flow was achieved in 93.3% patients with p<0.0001 and 46.6% patients showed normal findings on pelvic ultrasonography with p=0.006. In addition, significant changes were also observed in BMI, hirsutism and acanthosis nigricans with p value of 0.0001, p=0.003 and p=0.009 respectivelyConclusion: Majoon idraare haiz can be used as an effective alternative in management of PCOS patients. It has significant effect on menstrual regulation and changes in polycystic ovarian morphology to normal.
KW - Polycystic ovarian syndrome;Unani formulation;Majoon idraare haiz;Arq bedmushk;Pelvic ultrasonography
DO - 10.5667/CellMed.2022.003
ER -
Kouser fathima Firdose and Wajeeha Begum. (2022). Effect of Majoon Idraare Haiz in Polycystic Ovarian Syndrome - A pilot study. CELLMED, 12(1), 3-3.
Kouser fathima Firdose and Wajeeha Begum. 2022, "Effect of Majoon Idraare Haiz in Polycystic Ovarian Syndrome - A pilot study", CELLMED, vol.12, no.1 pp.3-3. Available from: doi:10.5667/CellMed.2022.003
Kouser fathima Firdose, Wajeeha Begum "Effect of Majoon Idraare Haiz in Polycystic Ovarian Syndrome - A pilot study" CELLMED 12.1 pp.3-3 (2022) : 3.
Kouser fathima Firdose, Wajeeha Begum. Effect of Majoon Idraare Haiz in Polycystic Ovarian Syndrome - A pilot study. 2022; 12(1), 3-3. Available from: doi:10.5667/CellMed.2022.003
Kouser fathima Firdose and Wajeeha Begum. "Effect of Majoon Idraare Haiz in Polycystic Ovarian Syndrome - A pilot study" CELLMED 12, no.1 (2022) : 3-3.doi: 10.5667/CellMed.2022.003
Kouser fathima Firdose; Wajeeha Begum. Effect of Majoon Idraare Haiz in Polycystic Ovarian Syndrome - A pilot study. CELLMED, 12(1), 3-3. doi: 10.5667/CellMed.2022.003
Kouser fathima Firdose; Wajeeha Begum. Effect of Majoon Idraare Haiz in Polycystic Ovarian Syndrome - A pilot study. CELLMED. 2022; 12(1) 3-3. doi: 10.5667/CellMed.2022.003
Kouser fathima Firdose, Wajeeha Begum. Effect of Majoon Idraare Haiz in Polycystic Ovarian Syndrome - A pilot study. 2022; 12(1), 3-3. Available from: doi:10.5667/CellMed.2022.003
Kouser fathima Firdose and Wajeeha Begum. "Effect of Majoon Idraare Haiz in Polycystic Ovarian Syndrome - A pilot study" CELLMED 12, no.1 (2022) : 3-3.doi: 10.5667/CellMed.2022.003